vs
Side-by-side financial comparison of TSS, Inc. (TSSI) and ZEVRA THERAPEUTICS, INC. (ZVRA). Click either name above to swap in a different company.
TSS, Inc. is the larger business by last-quarter revenue ($60.9M vs $34.1M, roughly 1.8× ZEVRA THERAPEUTICS, INC.). On growth, ZEVRA THERAPEUTICS, INC. posted the faster year-over-year revenue change (183.4% vs 21.8%). TSS, Inc. produced more free cash flow last quarter ($15.8M vs $5.5M). Over the past eight quarters, ZEVRA THERAPEUTICS, INC.'s revenue compounded faster (215.7% CAGR vs 95.8%).
Zevra Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients with rare under-treated orphan diseases, with a primary focus on central nervous system and metabolic rare disorder segments. Its main target markets are North America and the European Union.
TSSI vs ZVRA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $60.9M | $34.1M |
| Net Profit | $12.2M | — |
| Gross Margin | 17.6% | — |
| Operating Margin | 1.5% | 27.3% |
| Net Margin | 20.0% | — |
| Revenue YoY | 21.8% | 183.4% |
| Net Profit YoY | 535.7% | — |
| EPS (diluted) | $0.44 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $60.9M | $34.1M | ||
| Q3 25 | $41.9M | $26.1M | ||
| Q2 25 | $44.0M | $25.9M | ||
| Q1 25 | $99.0M | $20.4M | ||
| Q4 24 | $50.0M | $12.0M | ||
| Q3 24 | $70.1M | $3.7M | ||
| Q2 24 | $12.2M | $4.4M | ||
| Q1 24 | $15.9M | $3.4M |
| Q4 25 | $12.2M | — | ||
| Q3 25 | $-1.5M | $-544.0K | ||
| Q2 25 | $1.5M | $74.7M | ||
| Q1 25 | $3.0M | $-3.1M | ||
| Q4 24 | $1.9M | — | ||
| Q3 24 | $2.6M | $-33.2M | ||
| Q2 24 | $1.4M | $-19.9M | ||
| Q1 24 | $15.0K | $-16.6M |
| Q4 25 | 17.6% | — | ||
| Q3 25 | 11.1% | — | ||
| Q2 25 | 17.8% | — | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 14.4% | — | ||
| Q3 24 | 11.3% | — | ||
| Q2 24 | 37.3% | — | ||
| Q1 24 | 17.1% | — |
| Q4 25 | 1.5% | 27.3% | ||
| Q3 25 | -2.2% | 15.9% | ||
| Q2 25 | 5.1% | -274.5% | ||
| Q1 25 | 4.2% | -26.3% | ||
| Q4 24 | 0.0% | -128.0% | ||
| Q3 24 | 5.4% | -739.0% | ||
| Q2 24 | 14.0% | -534.8% | ||
| Q1 24 | 1.6% | -598.1% |
| Q4 25 | 20.0% | — | ||
| Q3 25 | -3.6% | -2.1% | ||
| Q2 25 | 3.4% | 288.7% | ||
| Q1 25 | 3.0% | -15.2% | ||
| Q4 24 | 3.8% | — | ||
| Q3 24 | 3.8% | -899.2% | ||
| Q2 24 | 11.5% | -447.9% | ||
| Q1 24 | 0.1% | -485.3% |
| Q4 25 | $0.44 | — | ||
| Q3 25 | $-0.06 | $-0.01 | ||
| Q2 25 | $0.06 | $1.21 | ||
| Q1 25 | $0.12 | — | ||
| Q4 24 | $0.08 | — | ||
| Q3 24 | $0.10 | $-0.69 | ||
| Q2 24 | $0.06 | $-0.48 | ||
| Q1 24 | $0.00 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $85.5M | $62.4M |
| Total DebtLower is stronger | — | $61.9M |
| Stockholders' EquityBook value | $76.6M | $154.7M |
| Total Assets | $184.9M | $284.7M |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $85.5M | $62.4M | ||
| Q3 25 | $70.7M | $54.4M | ||
| Q2 25 | — | $47.7M | ||
| Q1 25 | — | $37.3M | ||
| Q4 24 | $23.2M | $33.8M | ||
| Q3 24 | $46.4M | $54.0M | ||
| Q2 24 | $8.3M | $39.3M | ||
| Q1 24 | $14.4M | $42.8M |
| Q4 25 | — | $61.9M | ||
| Q3 25 | — | $61.3M | ||
| Q2 25 | — | $60.7M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $59.5M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $76.6M | $154.7M | ||
| Q3 25 | $63.4M | $133.2M | ||
| Q2 25 | $9.5M | $117.2M | ||
| Q1 25 | $9.4M | $41.0M | ||
| Q4 24 | $7.1M | $39.7M | ||
| Q3 24 | $7.7M | $69.8M | ||
| Q2 24 | $5.2M | $32.5M | ||
| Q1 24 | $3.7M | $48.8M |
| Q4 25 | $184.9M | $284.7M | ||
| Q3 25 | $165.4M | $270.1M | ||
| Q2 25 | $139.5M | $256.3M | ||
| Q1 25 | $113.5M | $172.7M | ||
| Q4 24 | $96.6M | $178.1M | ||
| Q3 24 | $67.3M | $191.6M | ||
| Q2 24 | $28.9M | $144.4M | ||
| Q1 24 | $26.8M | $151.3M |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.46× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.50× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $16.3M | $5.5M |
| Free Cash FlowOCF − Capex | $15.8M | $5.5M |
| FCF MarginFCF / Revenue | 25.9% | 16.1% |
| Capex IntensityCapex / Revenue | 0.9% | 0.1% |
| Cash ConversionOCF / Net Profit | 1.34× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.1M | $-2.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $16.3M | $5.5M | ||
| Q3 25 | $-18.4M | $4.7M | ||
| Q2 25 | $16.3M | $-3.6M | ||
| Q1 25 | $20.6M | $-8.2M | ||
| Q4 24 | $-21.6M | $-16.3M | ||
| Q3 24 | $38.6M | $-18.1M | ||
| Q2 24 | $-4.3M | $-19.1M | ||
| Q1 24 | $2.6M | $-16.2M |
| Q4 25 | $15.8M | $5.5M | ||
| Q3 25 | $-24.9M | $4.2M | ||
| Q2 25 | $5.4M | $-3.8M | ||
| Q1 25 | $5.8M | $-8.3M | ||
| Q4 24 | $-28.4M | — | ||
| Q3 24 | $38.6M | — | ||
| Q2 24 | $-6.0M | — | ||
| Q1 24 | $2.6M | — |
| Q4 25 | 25.9% | 16.1% | ||
| Q3 25 | -59.3% | 15.9% | ||
| Q2 25 | 12.3% | -14.7% | ||
| Q1 25 | 5.8% | -40.8% | ||
| Q4 24 | -56.7% | — | ||
| Q3 24 | 55.1% | — | ||
| Q2 24 | -49.4% | — | ||
| Q1 24 | 16.4% | — |
| Q4 25 | 0.9% | 0.1% | ||
| Q3 25 | 15.3% | 2.1% | ||
| Q2 25 | 24.8% | 0.8% | ||
| Q1 25 | 15.0% | 0.5% | ||
| Q4 24 | 13.4% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 13.8% | 0.0% | ||
| Q1 24 | 0.2% | 0.0% |
| Q4 25 | 1.34× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 11.02× | -0.05× | ||
| Q1 25 | 6.93× | — | ||
| Q4 24 | -11.32× | — | ||
| Q3 24 | 14.60× | — | ||
| Q2 24 | -3.09× | — | ||
| Q1 24 | 176.40× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
TSSI
| Procurement Revenues Segment | $43.2M | 71% |
| System Integration Services Segment | $14.2M | 23% |
| Facilities Segment | $3.5M | 6% |
ZVRA
| MIPLYFFA | $26.4M | 77% |
| Arimoclomol Purchase Agreement | $5.7M | 17% |
| Other | $2.0M | 6% |
